Diametric Capital, LP Cerevel Therapeutics Holdings, Inc. Transaction History

Diametric Capital, LP

  • $118 Million
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$38.96 - $42.75 $548,673 - $602,048
-14,083 Reduced 51.03%
13,517 $552,000
Q1 2024

May 15, 2024
BUY
$40.88 - $43.27 $481,321 - $509,460
11,774 Added 74.4%
27,600 $1.17 Million
Q4 2023

Feb 13, 2024
BUY
$20.27 - $42.44 $320,793 - $671,655
15,826 New
15,826 $671,000

Others Institutions Holding CERE

# of Institutions
7
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Diametric Capital, LP Portfolio

Follow Diametric Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Diametric Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email